University of Zagreb, Faculty of Pharmacy and Biochemistry, A. Kovačića 1, HR-10 000 Zagreb, Croatia.
University of Zagreb, Faculty of Science, Horvatovac 102 1, HR-10 000 Zagreb, Croatia.
Eur J Med Chem. 2016 Nov 29;124:622-636. doi: 10.1016/j.ejmech.2016.08.021. Epub 2016 Aug 24.
A series of novel compounds 3a-j and 6a-j with primaquine and hydroxyl or halogen substituted benzene moieties bridged by urea or bis-urea functionalities were designed, synthesized and evaluated for biological activity. The title compounds were prepared using benzotriazole as the synthon, through several synthetic steps. 3-[3,5-Bis(trifluoromethyl)phenyl]-1-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}urea (3j) was the most active urea and 1-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]-3-[3-(trifluoromethyl)phenyl]urea (6h) the most active bis-urea derivative in antiproliferative screening in vitro against eight tested cancer cell lines. Urea derivatives 3a-g with hydroxy group or one halogen atom showed moderate antiproliferative effects against all the tested cell lines, but stronger activity against breast carcinoma MCF-7 cell line, while trifluoromethyl derivatives 3h-j showed antiproliferative effects against all the tested cell lines in low micromolar range. Finally, bis-ureas with hydroxy and fluoro substituents 6a-d showed extreme selectivity and chloro or bromo derivatives 6e-g high selectivity against MCF-7 cells (IC 0.1-2.6 μM). p-Fluoro derivative 6d, namely 3-(4-fluorophenyl)-1-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]urea, is the most promising compound. Further biological experiments showed that 6d affected cell cycle and induced cell death of MCF-7 cell line. Due to its high activity against MCF-7 cell line (IC 0.31 μM), extreme selectivity and full agreement with the Lipinski's and Gelovani's rules for prospective small molecular drugs, 6d may be considered as a lead compound in development of breast carcinoma drugs. Urea 3b and almost all bis-ureas showed high antioxidant activity in DPPH assay, but urea derivatives were more active in lipid peroxidation test. Only few compounds exhibited weak inhibition of soybean lipoxygenase. Compound 3j exhibited the strongest antimicrobial activity in susceptibility assay in vitro (MIC = 1.6-12.5 μg ml).
设计、合成并评价了一系列具有前药和羟基或卤素取代苯部分桥连脲或双脲功能的新型化合物 3a-j 和 6a-j。使用苯并三唑作为合成子,通过几个合成步骤制备了标题化合物。3-[3,5-双(三氟甲基)苯基]-1-{4-[(6-甲氧基喹啉-8-基)氨基]戊基}脲(3j)是最具活性的脲,1-[({4-[(6-甲氧基喹啉-8-基)氨基]戊基}羰基)氨基]-3-[3-(三氟甲基)苯基]脲(6h)是最具活性的双脲衍生物,在体外对八种测试的癌细胞系的抗增殖筛选中具有活性。具有羟基或一个卤素原子的脲衍生物 3a-g 对所有测试的细胞系表现出中等的抗增殖作用,但对乳腺癌 MCF-7 细胞系的活性更强,而三氟甲基衍生物 3h-j 在低微摩尔范围内对所有测试的细胞系均表现出抗增殖作用。最后,具有羟基和氟取代基的双脲 6a-d 表现出对 MCF-7 细胞的极高选择性,而氯或溴取代基 6e-g 则对 MCF-7 细胞表现出高选择性(IC 0.1-2.6 μM)。对氟衍生物 6d,即 3-(4-氟苯基)-1-[({4-[(6-甲氧基喹啉-8-基)氨基]戊基}羰基)氨基]脲,是最有前途的化合物。进一步的生物学实验表明,6d 影响 MCF-7 细胞系的细胞周期并诱导细胞死亡。由于其对 MCF-7 细胞系的高活性(IC 0.31 μM)、极高的选择性以及完全符合潜在小分子药物的 Lipinski 和 Gelovani 规则,6d 可被视为开发乳腺癌药物的先导化合物。脲 3b 和几乎所有的双脲在 DPPH 测定中均表现出高抗氧化活性,但脲衍生物在脂质过氧化试验中更具活性。只有少数化合物表现出对大豆脂氧合酶的弱抑制作用。化合物 3j 在体外敏感性测定中表现出最强的抗菌活性(MIC = 1.6-12.5 μg ml)。